1. Home
  2. Labeler Index
  3. Quality Care Products, Llc
  4. 83008-046
  5. Product Images: Duloxetine

Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. image description - 30mg label
  2. Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01
  3. Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02
  4. Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03
  5. Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04
  6. Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05
  7. fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06
  8. fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07
  9. Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08
  10. Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09
  11. Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10
  12. Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11

Product Label Images

The following 12 images provide visual information about the product associated with Duloxetine NDC 83008-046 by Quality Care Products, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

image description - 30mg label

image description - 30mg label

Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01

Structure - 69d6387b 794f 415d 8013 23cca0a6984f 01

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 02

This is a graph showing the proportion of patients with relapse over time for both the placebo and duloxetine treatment groups. The Kaplan-Meier estimator method is used to analyze the time from randomization to relapse in days. The graph shows a trend where the duloxetine treatment has a potentially lower relapse rate compared to the placebo treatment.*

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 03

This text provides data on the proportion of patients with relapse over time for two treatments: Placebo and Duloxetine. The graph displays the time from randomization to relapse in days, using the Kaplan-Meier estimator method. The number of patients experiencing relapse under each treatment at different time points is shown.*

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04

Figure 1 - 69d6387b 794f 415d 8013 23cca0a6984f 04

This data shows the percentage of patients improved with different medications for pain relief. It includes Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and a placebo. The percentage improvement in pain from the baseline is also provided.*

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05

Figure 2 - 69d6387b 794f 415d 8013 23cca0a6984f 05

fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06

fig 5 - 69d6387b 794f 415d 8013 23cca0a6984f 06

This text provides information on the percentage of patients improved with Duloxetine at different doses compared to placebo. It shows the percent improvement in pain from baseline for Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and Placebo. The data includes various percentage levels of improvement and dosages for comparison.*

fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07

fig 6 - 69d6387b 794f 415d 8013 23cca0a6984f 07

This text provides information on the percentage of patients improved with different treatments for pain. It shows the comparison between Duloxetine 120mg twice daily, Duloxetine 60mg once daily, and Placebo. The chart also indicates the percent improvement in pain from the baseline.*

Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08

Fig 7 - 69d6387b 794f 415d 8013 23cca0a6984f 08

Percentage of Pediatric Patients Aged 13 to 17 Years old with Juvenile Fibromyalgia Syndrome Achieving Various Levels of Pain Relief at week 12 (Study FM-4). The study compared the percentage of patients with improved pain relief when treated with Duloxetine 60mg Once Daily compared to Placebo. The pain relief was measured using the Brief Pain Inventory - Modified short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30 mg once daily for 1 week and then increased to 60 mg once daily for 12 weeks depending on tolerance levels.*

Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09

Figure 8 - 69d6387b 794f 415d 8013 23cca0a6984f 09

Percentage of Patients Improved indicates the percentage of patients who saw improvement in pain levels compared to the baseline. The data shows the comparison between a placebo group and a group taking Duloxetine at 60/120 mg once daily. The percentage of improvement in pain is plotted on the x-axis, and the counts of patients or participants on the y-axis.*

Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10

Figure 9 - 69d6387b 794f 415d 8013 23cca0a6984f 10

This description provides data on the percentage of patients improved with the use of placebo compared to Duloxetine 60 mg taken once daily. It also shows the percent improvement in pain from baseline using the BOCF method.*

Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11

Figure 10 - 69d6387b 794f 415d 8013 23cca0a6984f 11

This text provides information on the percentage of patients improved with placebo and duloxetine 60/120 mg once daily. It also includes a graph showing the percentage improvement in pain from baseline using the Last Observation Carried Forward (BOCF) method.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.